{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T23:01:58Z","timestamp":1775689318487,"version":"3.50.1"},"reference-count":54,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Recent progress has notably improved outcomes for patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), namely granulomatosis with polyangiitis and microscopic polyangiitis. Since 2021, several international scientific societies have recommended rituximab (RTX) as the preferred primary treatment for maintaining remission in AAV patients. Decisions regarding retreatment with RTX are based on individual patient risk factors for disease flare-ups and the potential consequences of such flares. In reviewing available evidence and reporting our experiences at G. Bosco Hub Hospital in Turin, Italy, we explore various trials focusing on the maintenance therapy in AAV and discuss areas of unmet need.<\/jats:p>","DOI":"10.3390\/jcm14010208","type":"journal-article","created":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T06:05:10Z","timestamp":1735797910000},"page":"208","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["How We Treat ANCA-Associated Vasculitis: A Focus on the Maintenance Therapy"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4419-6813","authenticated-orcid":false,"given":"Dario","family":"Roccatello","sequence":"first","affiliation":[{"name":"University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-Net, ERN-Reconnet and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hub Hospital, ASL Citt\u00e0 di Torino and University of Torino, 10154 Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8019-5749","authenticated-orcid":false,"given":"Roberta","family":"Fenoglio","sequence":"additional","affiliation":[{"name":"University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-Net, ERN-Reconnet and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hub Hospital, ASL Citt\u00e0 di Torino and University of Torino, 10154 Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuele","family":"De Simone","sequence":"additional","affiliation":[{"name":"University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-Net, ERN-Reconnet and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hub Hospital, ASL Citt\u00e0 di Torino and University of Torino, 10154 Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1266-9441","authenticated-orcid":false,"given":"Savino","family":"Sciascia","sequence":"additional","affiliation":[{"name":"University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-Net, ERN-Reconnet and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hub Hospital, ASL Citt\u00e0 di Torino and University of Torino, 10154 Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1136\/annrheumdis-2021-221795","article-title":"2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis","volume":"81","author":"Robson","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/annrheumdis-2021-221796","article-title":"2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis","volume":"81","author":"Suppiah","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13063-017-1857-z","article-title":"Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): Study protocol for a randomized controlled trial","volume":"18","author":"Gopaluni","year":"2017","journal-title":"Trials"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1136\/annrheumdis-2017-211123","article-title":"Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis","volume":"76","author":"Karras","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1136\/annrheumdis-2017-212878","article-title":"Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: Results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)","volume":"77","author":"Charles","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/cei\/uxae068","article-title":"An update on risk factors for relapse in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"218","author":"Zhou","year":"2024","journal-title":"Clin. Exp. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/rheumatology\/keu452","article-title":"Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis","volume":"54","author":"Alberici","year":"2015","journal-title":"Rheumatology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1002\/art.34583","article-title":"Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis","volume":"64","author":"Smith","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1093\/rheumatology\/ket381","article-title":"Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: A multicentre retrospective study on 80 patients","volume":"53","author":"Charles","year":"2014","journal-title":"Rheumatology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"736","DOI":"10.2215\/CJN.07340713","article-title":"Long-term maintenance therapy using rituximab-induced continuous B-cell depletion in patients with ANCA vasculitis","volume":"9","author":"Pendergraft","year":"2014","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"103438","DOI":"10.1016\/j.autrev.2023.103438","article-title":"Might maintenance therapy be discontinued once clinical remission is achieved in ANCA- associated vasculitis?","volume":"23","author":"Roccatello","year":"2024","journal-title":"Autoimmun. Rev."},{"key":"ref_15","first-page":"S67","article-title":"Effects of anti-CD20 monoclonal antibody as a rescue treatment for ANCA-associated idiopathic systemic vasculitis with or without overt renal involvement","volume":"26","author":"Roccatello","year":"2008","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1159\/000329535","article-title":"Long-term effects of rituximab added to cyclophosphamide in refractory patients with vasculitis","volume":"34","author":"Roccatello","year":"2011","journal-title":"Am. J. Nephrol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Roccatello, D., Sciascia, S., Murgia, S., Quattrocchio, G., Ferro, M., De Simone, E., Naretto, C., Barreca, A., Sammartino, A., and Rossi, D. (2022). Treating Patients with ANCA-Associated Vasculitis and Very Severe Renal Injury with an Intensified B Cell Depletion Therapy: Comparison with a Control Cohort Receiving a Conventional Therapy. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.777134"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1093\/ndt\/gfr109","article-title":"Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy","volume":"26","author":"Roccatello","year":"2011","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.autrev.2015.07.017","article-title":"A 4-year observation in lupus nephritis patients treated with an intensified B-lymphocyte depletion without immunosuppressive maintenance treatment-Clinical response compared to literature and immunological re-assessment","volume":"14","author":"Roccatello","year":"2015","journal-title":"Autoimmun. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Rossi, D., Sciascia, S., Cecchi, I., Saracco, M., Montabone, E., Modena, V., Pellerito, R., Carignola, R., and Roccatello, D. (2021). A 3-Year Observational Study of Patients with Progressive Systemic Sclerosis Treated with an Intensified B Lymphocyte Depletion Protocol: Clinical and Immunological Response. J. Clin. Med., 10.","DOI":"10.3390\/jcm10020292"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.ekir.2021.01.027","article-title":"A Prospective Study on Long-Term Clinical Outcomes of Patients with Lupus Nephritis Treated with an Intensified B-Cell Depletion Protocol Without Maintenance Therapy","volume":"6","author":"Roccatello","year":"2021","journal-title":"Kidney Int. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Arnold, J., Vital, E.M., Dass, S., Aslam, A., Rawstron, A.C., Savic, S., Emery, P., and Md Yusof, M.Y. (2022). A Personalized Rituximab Retreatment Approach Based on Clinical and B-Cell Biomarkers in ANCA-Associated Vasculitis. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.803175"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/annrheumdis-2017-212768","article-title":"Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides","volume":"77","author":"Terrier","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2215\/CJN.06460622","article-title":"Maintenance of Remission and Risk of Relapse in Myeloperoxidase-Positive ANCA-Associated Vasculitis with Kidney Involvement","volume":"18","author":"Moura","year":"2023","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ekir.2019.01.004","article-title":"Understanding long-term remission off therapy in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"4","author":"Hogan","year":"2019","journal-title":"Kidney Int. Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1213277","article-title":"Efficacy of remission-induction regimens for ANCA-associated vasculitis","volume":"369","author":"Specks","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1136\/annrheumdis-2011-200477","article-title":"Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: Long-term follow-up","volume":"71","author":"Harper","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"179","DOI":"10.7326\/M19-3827","article-title":"Long-term rituximab use to maintain remission of antineutrophil cytoplasmic antibody-associated vasculitis: A randomized trial","volume":"173","author":"Charles","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1136\/annrheumdis-2012-201750","article-title":"Revisiting the classification of clinical phenotypes of anti-neutrophil cytoplasmic antibody-associated vasculitis: A cluster analysis","volume":"72","author":"Mahr","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/RHU.0000000000001030","article-title":"Evaluation of PR3-ANCA status after rituximab for ANCA-associated vasculitis","volume":"25","author":"McClure","year":"2019","journal-title":"J. Clin. Rheumatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/art.33361","article-title":"Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"64","author":"Walsh","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/rheumatology\/key260","article-title":"Renal relapse in antineutrophil cytoplasmic autoantibody-associated vasculitis: Unpredictable, but predictive of renal outcome","volume":"58","author":"Westman","year":"2019","journal-title":"Rheumatology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1681\/ASN.2021030382","article-title":"The clinical application of urine soluble CD163 in ANCA-associated vasculitis","volume":"32","author":"Moran","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2215\/CJN.04160417","article-title":"The utility of urinalysis in determining the risk of renal relapse in ANCA-associated vasculitis","volume":"13","author":"Rhee","year":"2018","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1093\/rheumatology\/keab695","article-title":"Utility of interval kidney biopsy in ANCA-associated vasculitis","volume":"61","author":"Chapman","year":"2022","journal-title":"Rheumatology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.3899\/jrheum.100302","article-title":"Use of highly sensitive C-reactive protein for followup of Wegener\u2019s granulomatosis","volume":"37","author":"Csernok","year":"2010","journal-title":"J. Rheumatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0140-6736(23)01736-1","article-title":"Diagnosis and management of ANCA-associated vasculitis","volume":"403","author":"Kronbichler","year":"2024","journal-title":"Lancet"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1001\/jama.2021.6615","article-title":"Effect of reduced-dose vs high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: A randomized clinical trial","volume":"325","author":"Furuta","year":"2021","journal-title":"JAMA"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the Treatment of ANCA-Associated Vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1056\/NEJMoa1803537","article-title":"Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis","volume":"382","author":"Walsh","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"15201","DOI":"10.1016\/j.semarthrit.2022.152010","article-title":"The glucocorticoid toxicity index: Measuring change in glucocorticoid toxicity over time","volume":"Volume 55","author":"Stone","year":"2022","journal-title":"Seminars in Arthritis and Rheumatism"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1016\/S2665-9913(23)00030-9","article-title":"Glucocorticoid toxicity index scores by domain in patients with antineutrophil cytoplasmic antibody-associated vasculitis treated with avacopan versus standard prednisone taper: Post-hoc analysis of data from the ADVOCATE trial","volume":"5","author":"Patel","year":"2023","journal-title":"Lancet Rheumatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e002160","DOI":"10.1136\/rmdopen-2021-002160","article-title":"Comparative study of granulomatosis with polyangiitis subsets according to ANCA status: Data from the French Vasculitis Study Group Registry","volume":"8","author":"Iudici","year":"2022","journal-title":"RMD Open"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Al-Soudi, A., Vegting, Y., Klarenbeek, P.L., and Hilhorst, M.L. (2022). Do Relapses Follow ANCA Rises? A Systematic Review and Meta-Analysis on the Value of Serial ANCA Level Evaluation. Front. Med., 9.","DOI":"10.3389\/fmed.2022.844112"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/cei.13530","article-title":"Relapse rate and renal prognosis in ANCA-associated vasculitis according to long-term ANCA patterns","volume":"203","author":"Oristrell","year":"2021","journal-title":"Clin. Exp. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1681\/ASN.2013111233","article-title":"ANCA as a predictor of relapse: Useful in patients with renal involvement but not in patients with nonrenal disease","volume":"26","author":"Kemna","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1046\/j.1523-1755.2003.00821.x","article-title":"Serial ANCA titers: Useful tool for prevention of relapses in ANCA-associated vasculitis","volume":"63","author":"Han","year":"2003","journal-title":"Kidney Int."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/art.38248","article-title":"Brief report: The value of a patient global assessment of disease activity in granulomatosis with polyangiitis (Wegener\u2019s)","volume":"66","author":"Tomasson","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e003477","DOI":"10.1136\/rmdopen-2023-003477","article-title":"Serum calprotectin and renal function decline in ANCA-associated vasculitides: A post hoc analysis of MAINRITSAN trial","volume":"9","author":"Romand","year":"2023","journal-title":"RMD Open"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"584916","DOI":"10.1155\/2009\/584916","article-title":"Monocyte chemoattractant protein 1 is a prognostic marker in ANCA-associated small vessel vasculitis","volume":"2009","author":"Ohlsson","year":"2009","journal-title":"Mediat. Inflamm."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Bayati, S., Nazeer, J., Ng, J., George, A.M., Hayes, M., Little, M.A., Nilsson, P., and Pin, E. (2024). Autoantibodies towards HFE and SYT5 in anti-neutrophil cytoplasm antibody-associated vasculitis relapse. Rheumatology, keae540.","DOI":"10.1101\/2024.07.25.24310702"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s13075-024-03393-8","article-title":"Serum syndecan1 has the potential to reflect activity at diagnosis and predict death during follow-up in patients with ANCA-associated vasculitis","volume":"26","author":"Yoon","year":"2024","journal-title":"Arthritis Res. Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1002\/art.42388","article-title":"Autoreactive Plasmablasts After B Cell Depletion With Rituximab and Relapses in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis","volume":"75","author":"Berti","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Wang, L., Novoa-Laurentiev, J., Cook, C., Srivatsan, S., Hua, Y., Yang, J., Miloslavsky, E., Choi, H.K., Zhou, L., and Wallace, Z.S. (2024). Identification of an ANCA-Associated Vasculitis Cohort Using Deep Learning and Electronic Health Records. medRxiv.","DOI":"10.1101\/2024.06.09.24308603"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/1\/208\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T15:23:34Z","timestamp":1759850614000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/1\/208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,2]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["jcm14010208"],"URL":"https:\/\/doi.org\/10.3390\/jcm14010208","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,2]]}}}